Free Daily Podcast Summary
The BioHub - by Avetix: Daily Summaries Delivered
by Max Brennan - Biotech HeadHunter
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Get ready for an immersive experience into the world of biotech with The BioHub.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- Today24 min
Episode 185 - Ed Ahn - Medipost INC
Today's guest is Edward Ahn, CEO of MEDIPOST Inc., a biotechnology company at the forefront of regenerative medicine and stem cell therapeutics. Based in Cambridge, Massachusetts, MEDIPOST is leading the global development of innovative cell therapies designed to address inflammation-driven degenerative diseases, with a mission to move beyond symptom management and toward true disease modification.Edward leads MEDIPOST's U.S. operations and global expansion efforts for CARTISTEM®, the world's first approved allogeneic stem cell therapy derived from umbilical cord blood. Since its approval in South Korea, CARTISTEM has been used to treat more than 30,000 patients, and under Edward's leadership the company is now advancing late-stage clinical development in the United States, with one of the most ambitious regenerative medicine programs in orthopedics today.What makes Edward's perspective particularly interesting is his focus on the practical realities of turning breakthrough science into scalable healthcare solutions. He has championed a strategy that combines clinical development, manufacturing infrastructure, regulatory execution, and long-term commercialization planning from day one. That vision has included building a North American presence, forming strategic manufacturing partnerships, and creating the operational foundation required to bring advanced cell therapies to patients around the world.As regenerative medicine moves from promise to reality, Edward has become a leading voice on how biotechnology companies can successfully navigate the path from scientific innovation to global commercialization. His work sits at the intersection of stem cell science, healthcare innovation, manufacturing strategy, and venture-backed growth—areas that will define the next generation of medicine.
- Yesterday29 min
Episode 184 - Randy Teel - President & CEO Arvinas
In this episode of The BioHub Podcast, Max sits down with Randy Teel, President and CEO of Arvinas.Randy joined Arvinas in 2018 as Vice President of Corporate Development and has since helped guide the company through a period of significant growth, ultimately stepping into the CEO role. Today, Arvinas is one of the pioneers in targeted protein degradation, using its PROTAC platform to develop therapies designed to eliminate disease-causing proteins.In this conversation, we discuss Randy’s journey from strategy and corporate development into the CEO seat, the evolution of Arvinas from an emerging platform company to an industry leader, and the challenges of building and scaling a biotech company.We also explore the future of targeted protein degradation, the company’s unique partnership approach, and what’s next for Arvinas and its pipeline.
- 3 days ago25 min
Episode 183 - Matt Erick - CCO Biocon Biologics
Matt Erick, Chief Commercial Officer for Advanced Markets at Biocon Biologics, joins Max on The BioHub Podcast.With more than two decades of experience across pharma, biologics, distribution, and healthcare services, Matt has helped shape commercial strategy across some of the industry's most complex and competitive markets.In this conversation, we discuss Biocon's expansion into the U.S., the integration of its generics and biosimilars businesses, the evolution of the biosimilars market, and the role these medicines play in improving patient access worldwide.We also explore the challenges of navigating policy and regulatory change, building long-term commercial strategies, and driving growth in a challenging market environment.
- 4 days ago23 min
Episode 182 - David Solomon - CEO of Thalia Therapeutics
We were delighted to be joined by Dr. David Solomon, Chief Executive Officer of Thalia Therapeutics, onto The BioHub!David brings more than three decades of leadership experience across the biotechnology, pharmaceutical, and healthcare sectors, having led multiple publicly listed and private biotech companies throughout Europe and the United States. Throughout his career, he has played a key role in advancing innovative therapies, scaling organisations, securing major strategic partnerships, and delivering significant shareholder value.Prior to joining Thalia Therapeutics, David served as CEO of companies including Zealand Pharma, where he led the business through its IPO and the global approval of its lead GLP-1 therapy, and Silence Therapeutics, helping position the company as a leading player in the RNA therapeutics space. He has also held numerous board positions and remains a highly respected figure across the global biotech ecosystem.At Thalia Therapeutics, David is leading the company’s strategic focus on next-generation RNA therapeutics and novel delivery technologies, with ambitions to address major unmet needs across cardiovascular disease, oncology, and beyond.
- 1 weeks ago27 min
Episode 181 - Pete Smith - Co-Founder, CEO & President of Remix Therapeutics
Today on the podcast, we’re joined by Peter Smith, co-founder and CEO of — a company pioneering a new frontier in RNA-processing therapeutics.Peter has spent more than two decades at the forefront of oncology and drug discovery, with leadership roles spanning Takeda, Millennium Pharmaceuticals, and H3 Biomedicine before launching Remix to tackle diseases through precision RNA modulation.Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. They're a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).
- 1 weeks ago27 min
Episode 180 - Ben Zimmer - CEO of Priovant Therapeutics
In this episode of The BioHub Podcast, Max sits down with Ben Zimmer, CEO of Priovant Therapeutics.Ben was among the first ten employees at Roivant, helping incubate and launch multiple biotech companies before going on to found Priovant in 2021.Priovant is a clinical-stage biotech focused on developing therapies for severe autoimmune diseases — one of the most active and fast-moving areas in biotech today.In this conversation, we talk about the early days of Roivant, the inspiration behind building Priovant, why autoimmune disease has become such a major focus across the industry, and what it takes to build teams and companies in high-stakes therapeutic areas.We also discuss leadership, decision-making, and what’s next for Priovant.
- 1 weeks ago30 min
Episode 179 - Tosh Butt - CEO of Navigator Medicines
Tosh joins the podcast to talk through Navigator Medicines' bispecific approach to Hidradenitis Suppurativa.Giving us the full picture, from NAV-240's Korean-origins & the 2024 $100million Series A lead by RA Capital & Forbion, to the work that went into their half-life extended next-gen molecule NAV-242 & the speedy clinical development plan that could lead to a step change in HS patient outcomes.We also discuss Tosh's learnings from a career in big pharma across the likes of GSK & AZ, why he had to 'scratch' his biotech 'itch' & the career learnings he's taking into his role at Navigator.
- 2 weeks ago34 min
Episode 178 - Kevin Finney - Chairman, President and CEO at Autobahn Therapeutics
In this episode, Ben sits down with Kevin Finney, President and CEO of Autobahn Therapeutics, for a conversation on biotech leadership, CNS drug development, and what it takes to build companies around difficult but high-impact areas of medicine.Kevin brings deep experience across company formation, financing, business development, and exits, including leadership roles at Abide Therapeutics, which was acquired by Lundbeck, and Zavante Therapeutics, which was later acquired by Nabriva.We discussed his career journey, the lessons learned from building and selling biotech companies, and why CNS remains one of the most challenging but important areas for therapeutic innovation.The conversation also explores Autobahn’s work in neuropsychiatry, including its focus on developing differentiated treatments for depression and related CNS disorders, as well as the strategic decisions that shape clinical development, team building, and long-term value creation.A thoughtful discussion on leadership, translational science, and the realities of advancing new medicines in neuroscience.
About The BioHub - by Avetix
Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Get ready for an immersive experience into the world of biotech with The BioHub.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The BioHub - by Avetix in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The BioHub - by Avetix daily summary?
It's a free AI-powered email that summarizes new episodes of The BioHub - by Avetix as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The BioHub - by Avetix podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The BioHub - by Avetix product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Max Brennan - Biotech HeadHunter.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The BioHub - by Avetix release new episodes?
The BioHub - by Avetix publishes daily. Our AI generates a summary within hours of each new episode.
What topics does The BioHub - by Avetix cover?
The BioHub - by Avetix covers topics including Science, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The BioHub - by Avetix summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.